Immune System Disorder and Cancer-Associated Cachexia

Area of Science:

• Oncology
• Immunology
• Metabolic Disorders

Background:

• Cancer-associated cachexia (CAC) is a complex metabolic syndrome characterized by progressive muscle and fat loss, significantly impacting cancer patient morbidity and mortality.
• Immune dysfunction, particularly cytokine imbalance, is a key driver of CAC progression, often unresponsive to conventional nutritional interventions.
• The interplay between CAC and the anti-cancer immune response remains incompletely understood, despite its clinical significance.

Purpose of the Study:

• To review and synthesize current pre-clinical and clinical evidence on the relationship between cancer-associated cachexia and the anti-cancer immune response.
• To explore how immunomodulatory mechanisms in CAC might influence the efficacy of anti-cancer therapies, especially immunotherapy.
• To identify potential therapeutic strategies targeting CAC to improve outcomes for cancer patients.

Main Methods:

• Review of pre-clinical studies examining the role of specific cytokines (e.g., IL-6, TNF-α) and cellular components (e.g., MDSCs) in CAC pathogenesis.
• Analysis of clinical studies investigating immune markers (e.g., cytokine levels, NLR) in cancer patients with CAC.
• Evaluation of emerging immunomodulatory agents and their potential impact on CAC and anti-cancer immunity.

Main Results:

• Pre-clinical data implicate cytokines like IL-1β, IL-6, IL-8, IFN-γ, TNF-α, and TGF-β in CAC, with IL-6 and TNF-α mediating wasting via JAK/STAT and NF-κB pathways.
• Myeloid-derived suppressor cells (MDSCs) contribute to CAC by promoting inflammation.
• Clinical studies show elevated pro-inflammatory cytokines and neutrophil-to-lymphocyte ratio (NLR) in CAC patients, suggesting immune dysregulation impacts anti-neoplastic responses.
• The immunomodulator R-ketorolac demonstrated efficacy in reversing weight loss and improving survival in pre-clinical models of CAC.

Conclusions:

• Immunomodulatory mechanisms underlying CAC are intrinsically linked to the anti-cancer immune response.
• Targeting CAC-related immune dysregulation holds promise for enhancing the effectiveness of anti-cancer therapies, particularly immunotherapies.
• Combination strategies involving immunomodulators and immunotherapy may offer significant benefits for cancer patients experiencing cachexia, warranting further investigation into their complex interplay.